Meeting
2014 ASCO Annual Meeting
A phase I trial of palbociclib and paclitaxel in metastatic breast cancer.
Authors
Amy Sanders Clark
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Amy Sanders Clark , Peter J. O'Dwyer , Daniel Heitjan , Priti Lal , Michael D Feldman , Maryann Gallagher , Colleen Redlinger , Christopher Colameco , David Lewis , Kelly Zafman , Melissa Langer , Mark Alan Rosen , Keerthi Gogineni , Angela R. Bradbury , Susan M. Domchek , Kevin R. Fox , Angela DeMichele
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01320592
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 527)
DOI
10.1200/jco.2014.32.15_suppl.527
Abstract #
527
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.
First Author: Elena Shagisultanova
Poster
2018 ASCO Annual Meeting
Phase I trial of lurbinectedin (PM1183) in Japanese patients with advanced tumors: Results of the dose escalation part.
First Author: Shunji Takahashi
Poster
2021 ASCO Annual Meeting
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
First Author: Akshara Singareeka Raghavendra
Poster
2018 ASCO Annual Meeting
An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
First Author: Jiayu Wang